0000869392-23-002583.txt : 20231121 0000869392-23-002583.hdr.sgml : 20231121 20231121124202 ACCESSION NUMBER: 0000869392-23-002583 CONFORMED SUBMISSION TYPE: NPORT-P PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20230930 FILED AS OF DATE: 20231121 DATE AS OF CHANGE: 20231121 PERIOD START: 20231231 FILER: COMPANY DATA: COMPANY CONFORMED NAME: PUTNAM VARIABLE TRUST CENTRAL INDEX KEY: 0000822671 IRS NUMBER: 046649095 STATE OF INCORPORATION: MA FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: NPORT-P SEC ACT: 1940 Act SEC FILE NUMBER: 811-05346 FILM NUMBER: 231426163 BUSINESS ADDRESS: STREET 1: 100 FEDERAL STREET CITY: BOSTON STATE: MA ZIP: 02110 BUSINESS PHONE: 6172921000 MAIL ADDRESS: STREET 1: 100 FEDERAL STREET CITY: BOSTON STATE: MA ZIP: 02110 FORMER COMPANY: FORMER CONFORMED NAME: PUTNAM CAPITAL MANAGER TRUST /MA/ DATE OF NAME CHANGE: 19920703 0000822671 S000003874 Putnam VT Global Health Care Fund C000010843 Class IA Shares C000010844 Class IB Shares NPORT-P 1 primary_doc.xml NPORT-P false 0000822671 XXXXXXXX S000003874 C000010844 C000010843 Putnam Variable Trust 811-05346 0000822671 549300TBVD21LYBGBD46 100 FEDERAL STREET BOSTON 02110 1-800-225-1581 Putnam VT Global Health Care Fund S000003874 OGC9MX44J30WCPCACY55 2023-12-31 2023-09-30 N 157536079.56 5411558.83 152124520.73 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0 N MSCI World Health Care IDX00851 ABBVIE INC FR5LCKFTG8054YNNRU85 COMMON STOCK 00287Y109 53200 NS USD 7929992 5.212829570109 Long EC CORP US N 1 N N N DEXCOM INC 549300YSK3QDSFR5EU59 COMMON STOCK 252131107 58900 NS USD 5495370 3.612415653722 Long EC CORP US N 1 N N N INNOVIVA INC 549300ACOX4QTBES6535 COMMON STOCK 45781M101 514045 NS USD 6677444.55 4.389459712318 Long EC CORP US N 1 N N N OPTION CARE HEALTH INC 549300DI3Q5ACSYJRI17 COMMON STOCK 68404L201 113300 NS USD 3665255 2.409378174151 Long EC CORP US N 1 N N N HUMANA INC 529900YLDW34GJAO4J06 COMMON STOCK 444859102 7100 NS USD 3454292 2.270700333795 Long EC CORP US N 1 N N N MCKESSON CORP 549300WZWOM80UCFSF54 COMMON STOCK 58155Q103 9400 NS USD 4087590 2.687002713557 Long EC CORP US N 1 N N N INTUITIVE SURGICAL INC 54930052SRG011710797 COMMON STOCK 46120E602 26500 NS USD 7745685 5.091674217168 Long EC CORP US N 1 N N N JOHNSON AND JOHNSON 549300G0CFPGEF6X2043 COMMON STOCK 478160104 24432 NS USD 3805284 2.501427108358 Long EC CORP US N 1 N N N ELI LILLY AND CO FRDRIPF3EKNDJ2CQJL29 COMMON STOCK 532457108 20500 NS USD 11011165 7.238257808249 Long EC CORP US N 1 N N N REGENERON PHARMACEUTICALS INC 549300RCBFWIRX3HYQ56 COMMON STOCK 75886F107 5200 NS USD 4279392 2.813084951370 Long EC CORP US N 1 N N N STRYKER CORP 5493002F0SC4JTBU5137 COMMON STOCK 863667101 12900 NS USD 3525183 2.317300973626 Long EC CORP US N 1 N N N MERCK AND CO INC 4YV9Y5M8S0BRK1RP0397 COMMON STOCK 58933Y105 53662 NS USD 5524502.9 3.631566346760 Long EC CORP US N 1 N N N BOSTON SCIENTIFIC CORP Y6ZDD9FP4P8JSSJMW954 COMMON STOCK 101137107 116700 NS USD 6161760 4.050471265534 Long EC CORP US N 1 N N N THERMO FISHER SCIENTIFIC INC HCHV7422L5HDJZCRFL38 COMMON STOCK 883556102 12500 NS USD 6327125 4.159174976945 Long EC CORP US N 1 N N N UNITEDHEALTH GROUP INC 549300GHBMY8T5GXDE41 COMMON STOCK 91324P102 27800 NS USD 14016482 9.213821632922 Long EC CORP US N 1 N N N DANAHER CORP S4BKK9OTCEWQ3YHPFM11 COMMON STOCK 235851102 21600 NS USD 5358960 3.522745691677 Long EC CORP US N 1 N N N BIOGEN INC W8J5WZB5IY3K0NDQT671 COMMON STOCK 09062X103 7000 NS USD 1799070 1.182629855704 Long EC CORP US N 1 N N N KENVUE INC 5493008HSF8L4M2LIJ82 COMMON STOCK 49177J102 59391 NS USD 1192571.28 0.783944149357 Long EC CORP US N 1 N N N GREEN THUMB INDUSTRIES INC 529900Q0L3K192QQY915 COMMON STOCK 39342L108 27700 NS USD 308024 0.202481492479 Long EC CORP US N 1 N N N CURALEAF HOLDINGS INC N/A COMMON STOCK 23126M102 56742 NS USD 256473.84 0.168594674132 Long EC CORP US N 1 N N 4FRONT VENTURES CORP N/A COMMON STOCK 35086B207 4850921 NS USD 1212730.25 0.797195773686 Long EC CORP US N 1 N N N CIGNA GROUP/THE 549300VIWYMSIGT1U456 COMMON STOCK 125523100 12200 NS USD 3490054 2.294208706954 Long EC CORP US N 1 N N N ROCKET PHARMACEUTICALS INC 549300R7VV82YUIN4Y93 COMMON STOCK 77313F106 73989 NS USD 1516034.61 0.996574781452 Long EC CORP US N 1 N N N IQVIA HOLDINGS INC 549300W3R20NM4KQPH86 COMMON STOCK 46266C105 10900 NS USD 2144575 1.409749716685 Long EC CORP US N 1 N N N ASCENDIS PHARMA A/S 549300B66JN3W3J8GH73 COMMON STOCK - ADR 04351P101 48144 NS USD 4508204.16 2.963496048084 Long EC CORP DK N 1 N N BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 CURRENCY FORWARDS N/A 1 NC N/A 3749289.45 2.464618742599 N/A DFE CORP US N 2 BANK OF AMERICA N.A. B4TYDEB6GKMZO031MB27 3749289.45 USD 3864024.85 CHF 2023-12-20 -114735.4 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 4599191.58 3.023307194613 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 4599191.58 USD 4741346.5 CHF 2023-12-20 -142154.92 N N N UBS AG BFM8T61CT2L1QCEMIK50 CURRENCY FORWARDS N/A 1 NC N/A 1249769.25 0.821543590739 N/A DFE CORP US N 2 UBS AG BFM8T61CT2L1QCEMIK50 1271388.63 DKK 1249769.25 USD 2023-12-20 21619.38 N N N NATWEST MARKETS PLC RR3QWICWWIPCS8A4S074 CURRENCY FORWARDS N/A 1 NC N/A 430060.28 0.282702800269 N/A DFE CORP GB N 2 NATWEST MARKETS PLC RR3QWICWWIPCS8A4S074 440311.75 DKK 430060.28 USD 2023-12-20 10251.47 N N N CITIBANK N.A. E57ODZWZ7FF32TWEFA76 CURRENCY FORWARDS N/A 1 NC N/A 2865777.51 1.883836672910 N/A DFE CORP US N 2 CITIBANK N.A. E57ODZWZ7FF32TWEFA76 2914921.03 DKK 2865777.51 USD 2023-12-20 49143.52 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 81520.93 0.053588290441 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 81520.93 USD 81857.31 DKK 2023-12-20 -336.38 N N N STATE STREET B AND T CO 571474TGEMMWANRLN572 CURRENCY FORWARDS N/A 1 NC N/A 665182.31 0.437261729278 N/A DFE CORP US N 2 STATE STREET B AND T CO 571474TGEMMWANRLN572 676698.6 DKK 665182.31 USD 2023-12-20 11516.29 N N N MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 CURRENCY FORWARDS N/A 1 NC N/A 218516.66 0.143643285745 N/A DFE CORP US N 2 MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 223220.88 GBP 218516.66 USD 2023-12-20 4704.22 N N N WESTPAC BANKING CORPORATION EN5TNI6CI43VEPAMHL14 CURRENCY FORWARDS N/A 1 NC N/A 498681.88 0.327811635893 N/A DFE CORP US N 2 WESTPAC BANKING CORPORATION EN5TNI6CI43VEPAMHL14 508925.64 GBP 498681.88 USD 2023-12-20 10243.76 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 764808.32 0.502751506680 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 780508.11 GBP 764808.32 USD 2023-12-20 15699.79 N N N JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 CURRENCY FORWARDS N/A 1 NC N/A 580350.96 0.381497313658 N/A DFE CORP US N 2 JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 592274.24 GBP 580350.96 USD 2023-12-20 11923.28 N N N GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 CURRENCY FORWARDS N/A 1 NC N/A 521266.01 0.342657454235 N/A DFE CORP US N 2 GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 531909.63 GBP 521266.01 USD 2023-12-20 10643.62 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 179542.56 0.118023418669 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 182125.42 EUR 179542.56 USD 2023-12-20 2582.86 N N N JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 CURRENCY FORWARDS N/A 1 NC N/A 277564.34 0.182458645502 N/A DFE CORP US N 2 JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 277564.34 USD 292758.41 JPY 2023-11-15 -15194.07 N N N MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 CURRENCY FORWARDS N/A 1 NC N/A 74303.74 0.048844025699 N/A DFE CORP US N 2 MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 74303.74 USD 78382.98 JPY 2023-11-15 -4079.24 N N N GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 CURRENCY FORWARDS N/A 1 NC N/A 1797588.49 1.181655975890 N/A DFE CORP US N 2 GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 1797588.49 USD 1895868.51 JPY 2023-11-15 -98280.02 N N N STATE STREET B AND T CO 571474TGEMMWANRLN572 CURRENCY FORWARDS N/A 1 NC N/A 683817.33 0.449511575595 N/A DFE CORP US N 2 STATE STREET B AND T CO 571474TGEMMWANRLN572 685853.71 CAD 683817.33 USD 2023-10-18 2036.38 N N N JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 CURRENCY FORWARDS N/A 1 NC N/A 433737.25 0.285119879372 N/A DFE CORP US N 2 JP MORGANCHASE BANK 7H6GLXDRUGQFU57RNE97 444362.29 CAD 433737.25 USD 2023-10-18 10625.04 N N N GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 CURRENCY FORWARDS N/A 1 NC N/A 222612.51 0.146335718221 N/A DFE CORP US N 2 GOLDMAN SACHS INTL FX W22LROWP2IHZNBB6K528 228070.22 CAD 222612.51 USD 2023-10-18 5457.71 N N N HSBC BANK USA 1IE8VN30JCEQV1H4R804 CURRENCY FORWARDS N/A 1 NC N/A 389751.1 0.256205310051 N/A DFE CORP US N 2 HSBC BANK USA 1IE8VN30JCEQV1H4R804 389751.1 USD 403176.16 AUD 2023-10-18 -13425.06 N N N NATWEST MARKETS PLC RR3QWICWWIPCS8A4S074 CURRENCY FORWARDS N/A 1 NC N/A 2327378.22 1.529916550489 N/A DFE CORP GB N 2 NATWEST MARKETS PLC RR3QWICWWIPCS8A4S074 2327378.22 USD 2408008.36 AUD 2023-10-18 -80630.14 N N N STATE STREET B AND T CO 571474TGEMMWANRLN572 CURRENCY FORWARDS N/A 1 NC N/A 1811662.48 1.190907600764 N/A DFE CORP US N 2 STATE STREET B AND T CO 571474TGEMMWANRLN572 1811662.48 USD 1868078.8 CHF 2023-12-20 -56416.32 N N N MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 CURRENCY FORWARDS N/A 1 NC N/A 1341857.93 0.882078657379 N/A DFE CORP US N 2 MORGAN STANLEY AND CO. INTERNATIONAL 4PQUHN3JPFGFNF3BB653 1341857.93 USD 1380602.19 CHF 2023-12-20 -38744.26 N N N ARGENX SE 7245009C5FZE6G9ODQ71 ORDINARY SHARES N/A 2172 NS 1055941.75 0.694129877901 Long EC CORP NL N 2 N N N ASTRAZENECA PLC PY6ZZQWO2IZFZC3IOL08 ORDINARY SHARES N/A 66178 NS 8906023.05 5.854429652276 Long EC CORP GB N 2 N N N TERUMO CORPORATION 353800JX1R4582QVK932 ORDINARY SHARES N/A 14000 NS 370889.22 0.243806335902 Long EC CORP JP N 2 N N N TERRASCEND CORP 529900Z66HBZ5381EO49 ORDINARY SHARES 88105E108 603012 NS USD 1236174.6 0.812607062995 Long EC CORP CA N 1 N N N DAIICHI SANKYO CO LTD 353800XGIU2IHQGC9504 ORDINARY SHARES N/A 52700 NS 1446394.92 0.950796698033 Long EC CORP JP N 2 N N N SANOFI SA 549300E9PC51EN656011 ORDINARY SHARES N/A 75298 NS 8079639.87 5.311201528345 Long EC CORP FR N 2 N N N NOVO NORDISK A/S 549300DAQ1CVT6CXN342 ORDINARY SHARES N/A 83706 NS 7614386.47 5.005364311724 Long EC CORP DK N 2 N N N EISAI CO LTD 353800HDEE0ZYEX4QV91 ORDINARY SHARES N/A 10700 NS 594008.68 0.390475300858 Long EC CORP JP N 2 N N N TAKEDA PHARMACEUTICAL CO LTD 549300ZLMVP4X0OGR454 ORDINARY SHARES J81281115 58800 NS 1826089.4 1.200391226370 Long EC CORP JP N 2 N N N PUTNAM CASH COLLATERAL POOL LLC 5493005HRIV7IFMKD774 SHORT TERM INV FUND N/A 4431580 NS USD 4431580 2.913126679863 Long STIV PF US N 2 N N State Street Institutional U.S. Government Money Market Fund, Premier Class N/A SHORT TERM INV FUND N/A 20000 NS USD 20000 0.013147124411 Long STIV RF US N 1 N N N PUTNAM SHORT TERM INVESTMENT FUND 5493003MK0Q7JP8CPP42 SHORT TERM INV FUND 74676P664 5550943 NS USD 5550943 3.648946910967 Long STIV PF US N 2 N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T BILLS 912797FC6 200000 PA USD 199295.56 0.131008176094 Long DBT UST US N 2 2023-10-26 Fixed 0 N N N N N N UNITED STATES OF AMERICA 254900HROIFWPRGM1V77 U.S. T BILLS 912797FT9 200000 PA USD 198051.16 0.130190162013 Long DBT UST US N 2 2023-12-07 Fixed 0 N N N N N N 2023-11-21 Putnam Investments Inc Janet C. Smith NPORT Principal Financial Officer XXXX NPORT-EX 2 b_2iwnport093023.htm QUARTERLY PORTFOLIO HOLDINGS
Putnam VT Global Health Care Fund
The fund's portfolio
9/30/23 (Unaudited)


COMMON STOCKS (96.5%)(a)
        Shares Value
Biotechnology (13.9%)
AbbVie, Inc. 53,200 $7,929,992
Argenx SE (Netherlands)(NON) 2,172 1,055,942
Ascendis Pharma A/S ADR (Denmark)(NON)(S) 48,144 4,508,204
Biogen, Inc.(NON) 7,000 1,799,070
Regeneron Pharmaceuticals, Inc.(NON) 5,200 4,279,392
Rocket Pharmaceuticals, Inc.(NON) 73,989 1,516,035

21,088,635
Health care equipment and supplies (15.3%)
Boston Scientific Corp.(NON) 116,700 6,161,760
Dexcom, Inc.(NON) 58,900 5,495,370
Intuitive Surgical, Inc.(NON) 26,500 7,745,685
Stryker Corp. 12,900 3,525,183
Terumo Corp. (Japan) 14,000 370,889

23,298,887
Health care providers and services (18.9%)
Cigna Corp. 12,200 3,490,054
Humana, Inc. 7,100 3,454,292
McKesson Corp. 9,400 4,087,590
Option Care Health, Inc.(NON) 113,300 3,665,255
UnitedHealth Group, Inc. 27,800 14,016,482

28,713,673
Life sciences tools and services (9.1%)
Danaher Corp. 21,600 5,358,960
IQVIA Holdings, Inc.(NON) 10,900 2,144,575
Thermo Fisher Scientific, Inc. 12,500 6,327,125

13,830,660
Personal care products (0.8%)
Kenvue, Inc. 59,391 1,192,571

1,192,571
Pharmaceuticals (38.5%)
4Front Ventures Corp.(NON) 4,850,921 1,212,730
AstraZeneca PLC (United Kingdom) 66,178 8,906,023
Curaleaf Holdings, Inc.(NON)(S) 56,742 256,474
Daiichi Sankyo Co., Ltd. (Japan) 52,700 1,446,395
Eisai Co., Ltd. (Japan) 10,700 594,009
Eli Lilly and Co. 20,500 11,011,165
Green Thumb Industries, Inc.(NON) 27,700 308,024
Innoviva, Inc.(NON) 514,045 6,677,445
Johnson & Johnson 24,432 3,805,284
Merck & Co., Inc. 53,662 5,524,503
Novo Nordisk A/S Class B (Denmark) 83,706 7,614,386
Sanofi (France) 75,298 8,079,640
Takeda Pharmaceutical Co., Ltd. (Japan) 58,800 1,826,089
TerrAscend Corp. (Canada)(NON) 603,012 1,236,175

58,498,342

Total common stocks (cost $106,000,914) $146,622,768









SHORT-TERM INVESTMENTS (6.8%)(a)
        Principal amount/shares Value
Putnam Cash Collateral Pool, LLC 5.62%(AFF) Shares 4,431,580 $4,431,580
Putnam Short Term Investment Fund Class P 5.57%(AFF) Shares 5,550,943 5,550,943
State Street Institutional U.S. Government Money Market Fund, Premier Class 5.29%(P) Shares 20,000 20,000
U.S. Treasury Bills 5.453%, 10/26/23(SEGSF) $200,000 199,296
U.S. Treasury Bills 5.437%, 12/7/23(SEGSF) 200,000 198,051

Total short-term investments (cost $10,399,835) $10,399,870
TOTAL INVESTMENTS

Total investments (cost $116,400,749) $157,022,638









FORWARD CURRENCY CONTRACTS at 9/30/23 (aggregate face value $26,494,675) (Unaudited)
  Counterparty Currency Contract type* Delivery
date
Value Aggregate face value Unrealized
appreciation/
(depreciation)
Bank of America N.A.
Swiss Franc Buy 12/20/23 $3,749,289 $3,864,025 $(114,736)
Citibank, N.A.
Danish Krone Sell 12/20/23 2,865,778 2,914,921 49,143
Goldman Sachs International
British Pound Sell 12/20/23 521,266 531,910 10,644
Canadian Dollar Sell 10/18/23 222,613 228,070 5,457
Japanese Yen Buy 11/15/23 1,797,588 1,895,869 (98,281)
HSBC Bank USA, National Association
Australian Dollar Buy 10/18/23 389,751 403,176 (13,425)
British Pound Sell 12/20/23 764,808 780,508 15,700
Danish Krone Buy 12/20/23 81,521 81,857 (336)
Euro Sell 12/20/23 179,543 182,125 2,582
Swiss Franc Buy 12/20/23 4,599,194 4,741,347 (142,153)
JPMorgan Chase Bank N.A.
British Pound Sell 12/20/23 580,351 592,274 11,923
Canadian Dollar Sell 10/18/23 433,737 444,362 10,625
Japanese Yen Buy 11/15/23 277,564 292,758 (15,194)
Morgan Stanley & Co. International PLC
British Pound Sell 12/20/23 218,517 223,221 4,704
Japanese Yen Buy 11/15/23 74,304 78,383 (4,079)
Swiss Franc Buy 12/20/23 1,341,858 1,380,602 (38,744)
NatWest Markets PLC
Australian Dollar Buy 10/18/23 2,327,378 2,408,008 (80,630)
Danish Krone Sell 12/20/23 430,061 440,312 10,251
State Street Bank and Trust Co.
Canadian Dollar Sell 10/18/23 683,817 685,854 2,037
Danish Krone Sell 12/20/23 665,182 676,699 11,517
Swiss Franc Buy 12/20/23 1,811,662 1,868,079 (56,417)
UBS AG
Danish Krone Sell 12/20/23 1,249,769 1,271,389 21,620
WestPac Banking Corp.
British Pound Sell 12/20/23 498,682 508,926 10,244

Unrealized appreciation 166,447

Unrealized (depreciation) (563,995)

Total $(397,548)
* The exchange currency for all contracts listed is the United States Dollar.













Key to holding's abbreviations
ADR American Depository Receipts: Represents ownership of foreign securities on deposit with a custodian bank.
Notes to the fund's portfolio
Unless noted otherwise, the notes to the fund's portfolio are for the close of the fund's reporting period, which ran from January 1, 2023 through September 30, 2023 (the reporting period). Within the following notes to the portfolio, references to "Putnam Management" represent Putnam Investment Management, LLC, the fund's manager, an indirect wholly-owned subsidiary of Putnam Investments, LLC, references to "ASC 820" represent Accounting Standards Codification 820 Fair Value Measurements and Disclosures and references to "OTC", if any, represent over-the-counter.
(a) Percentages indicated are based on net assets of $152,005,698.
(NON) This security is non-income-producing.
(AFF) Affiliated company. For investments in Putnam Cash Collateral Pool, LLC and Putnam Short Term Investment Fund, the rate quoted in the security description is the annualized 7-day yield of the fund at the close of the reporting period. Transactions during the period with any company which is under common ownership or control were as follows:
Name of affiliate Fair value
as of
12/31/22
Purchase
cost
Sale
proceeds
Investment
income
Shares outstanding
and fair
value as of
9/30/23
Short-term investments
Putnam Cash Collateral Pool, LLC*# $5,328,454 $29,204,667 $30,101,541 $158,597 $4,431,580
Putnam Short Term Investment Fund** 5,816,277 28,016,275 28,281,609 275,359 5,550,943





Total Short-term investments $11,144,731 $57,220,942 $58,383,150 $433,956 $9,982,523
* The fund may lend securities, through its agent, to qualified borrowers in order to earn additional income. The loans are collateralized by cash in an amount at least equal to the fair value of the securities loaned. The fair value of securities loaned is determined daily and any additional required collateral is allocated to the fund on the next business day. The remaining maturities of the securities lending transactions are considered overnight and continuous. The risk of borrower default will be borne by the fund’s agent; the fund will bear the risk of loss with respect to the investment of the cash collateral. The fund receives cash collateral, which is invested in Putnam Cash Collateral Pool, LLC, a limited liability company managed by an affiliate of Putnam Management. Investments in Putnam Cash Collateral Pool, LLC are valued at its closing net asset value each business day. There are no management fees charged to Putnam Cash Collateral Pool, LLC and there were no realized or unrealized gains or losses during the period.
# At the close of the reporting period, the fund received cash collateral of $4,431,580 for securities loaned. The rate quoted in the security description is the annualized 7-day yield at the close of the reporting period. At the close of the reporting period, the value of securities loaned amounted to $4,281,064.
** Management fees charged to Putnam Short Term Investment Fund have been waived by Putnam Management. There were no realized or unrealized gains or losses during the period.
(SEGSF) This security, in part or in entirety, was pledged and segregated with the custodian for collateral on certain derivative contracts at the close of the reporting period. Collateral at period end totaled $346,364.
(P) This security was pledged, or purchased with cash that was pledged, to the fund for collateral on certain derivative contracts. The rate quoted in the security description is the annualized 7-day yield of the fund at the close of the reporting period.
(S) This security is on loan, in part or in entirety, at the close of the reporting period.
Unless otherwise noted, the rates quoted in Short-term investments security descriptions represent the weighted average yield to maturity.
The dates shown on debt obligations are the original maturity dates.
DIVERSIFICATION BY COUNTRY
Distribution of investments by country of risk at the close of the reporting period, excluding collateral received, if any (as a percentage of Portfolio Value):
United States 76.7%
Denmark 7.9
United Kingdom 5.8
France 5.3
Japan 2.8
Canada 0.8
Netherlands 0.7

Total 100.0%
Methodology differs from that used for purposes of complying with the fund’s policy regarding investments in securities of foreign issuers, as discussed further in the fund’s prospectus.
Security valuation: Portfolio securities and other investments are valued using policies and procedures adopted by the Board of Trustees. The Trustees have formed a Pricing Committee to oversee the implementation of these procedures and have delegated responsibility for valuing the fund’s assets in accordance with these procedures to Putnam Management. Putnam Management has established an internal Valuation Committee that is responsible for making fair value determinations, evaluating the effectiveness of the pricing policies of the fund and reporting to the Pricing Committee.
Investments for which market quotations are readily available are valued at the last reported sales price on their principal exchange, or official closing price for certain markets, and are classified as Level 1 securities under ASC 820. If no sales are reported, as in the case of some securities that are traded OTC, a security is valued at its last reported bid price and is generally categorized as a Level 2 security.
Investments in open-end investment companies (excluding exchange-traded funds), if any, which can be classified as Level 1 or Level 2 securities, are valued based on their net asset value. The net asset value of such investment companies equals the total value of their assets less their liabilities and divided by the number of their outstanding shares.
Market quotations are not considered to be readily available for certain debt obligations (including short-term investments with remaining maturities of 60 days or less) and other investments; such investments are valued on the basis of valuations furnished by an independent pricing service approved by the Trustees or dealers selected by Putnam Management. Such services or dealers determine valuations for normal institutional-size trading units of such securities using methods based on market transactions for comparable securities and various relationships, generally recognized by institutional traders, between securities (which consider such factors as security prices, yields, maturities and ratings). These securities will generally be categorized as Level 2.
Many securities markets and exchanges outside the U.S. close prior to the scheduled close of the New York Stock Exchange and therefore the closing prices for securities in such markets or on such exchanges may not fully reflect events that occur after such close but before the scheduled close of the New York Stock Exchange. Accordingly, on certain days, the fund will fair value certain foreign equity securities taking into account multiple factors including movements in the U.S. securities markets, currency valuations and comparisons to the valuation of American Depository Receipts, exchange-traded funds and futures contracts. The foreign equity securities, which would generally be classified as Level 1 securities, will be transferred to Level 2 of the fair value hierarchy when they are valued at fair value. The number of days on which fair value prices will be used will depend on market activity and it is possible that fair value prices will be used by the fund to a significant extent. At the close of the reporting period, fair value pricing was used for certain foreign securities in the portfolio. Securities quoted in foreign currencies, if any, are translated into U.S. dollars at the current exchange rate.
To the extent a pricing service or dealer is unable to value a security or provides a valuation that Putnam Management does not believe accurately reflects the security's fair value, the security will be valued at fair value by Putnam Management, which has been designated as valuation designee pursuant to Rule 2a-5 under the Investment Company Act of 1940, in accordance with policies and procedures approved by the Trustees. Certain investments, including certain restricted and illiquid securities and derivatives, are also valued at fair value following procedures approved by the Trustees. These valuations consider such factors as significant market or specific security events such as interest rate or credit quality changes, various relationships with other securities, discount rates, U.S. Treasury, U.S. swap and credit yields, index levels, convexity exposures, recovery rates, sales and other multiples and resale restrictions. These securities are classified as Level 2 or as Level 3 depending on the priority of the significant inputs.
To assess the continuing appropriateness of fair valuations, the Valuation Committee reviews and affirms the reasonableness of such valuations on a regular basis after considering all relevant information that is reasonably available. Such valuations and procedures are reviewed periodically by the Trustees. The fair value of securities is generally determined as the amount that the fund could reasonably expect to realize from an orderly disposition of such securities over a reasonable period of time. By its nature, a fair value price is a good faith estimate of the value of a security in a current sale and does not reflect an actual market price, which may be different by a material amount.
Forward currency contracts: The fund buys and sells forward currency contracts, which are agreements between two parties to buy and sell currencies at a set price on a future date. These contracts were used to hedge foreign exchange risk.
The U.S. dollar value of forward currency contracts is determined using current forward currency exchange rates supplied by a quotation service. The fair value of the contract will fluctuate with changes in currency exchange rates. The contract is marked to market daily and the change in fair value is recorded as an unrealized gain or loss. The fund records a realized gain or loss equal to the difference between the value of the contract at the time it was opened and the value at the time it was closed when the contract matures or by delivery of the currency. The fund could be exposed to risk if the value of the currency changes unfavorably, if the counterparties to the contracts are unable to meet the terms of their contracts or if the fund is unable to enter into a closing position.
For the fund's average contract amount on forward currency contracts, see the appropriate table at the end of these footnotes.
Master agreements: The fund is a party to ISDA (International Swaps and Derivatives Association, Inc.) Master Agreements (Master Agreements) with certain counterparties that govern OTC derivative and foreign exchange contracts entered into from time to time. The Master Agreements may contain provisions regarding, among other things, the parties’ general obligations, representations, agreements, collateral requirements, events of default and early termination. With respect to certain counterparties, in accordance with the terms of the Master Agreements, collateral posted to the fund is held in a segregated account by the fund’s custodian and, with respect to those amounts which can be sold or repledged, is presented in the fund’s portfolio.
Collateral pledged by the fund is segregated by the fund’s custodian and identified in the fund’s portfolio. Collateral can be in the form of cash or debt securities issued by the U.S. Government or related agencies or other securities as agreed to by the fund and the applicable counterparty. Collateral requirements are determined based on the fund’s net position with each counterparty.
Termination events applicable to the fund may occur upon a decline in the fund’s net assets below a specified threshold over a certain period of time. Termination events applicable to counterparties may occur upon a decline in the counterparty’s long-term and short-term credit ratings below a specified level. In each case, upon occurrence, the other party may elect to terminate early and cause settlement of all derivative and foreign exchange contracts outstanding, including the payment of any losses and costs resulting from such early termination, as reasonably determined by the terminating party. Any decision by one or more of the fund’s counterparties to elect early termination could impact the fund’s future derivative activity.
At the close of the reporting period, the fund had a net liability position of $485,909 on open derivative contracts subject to the Master Agreements. Collateral posted by the fund at period end for these agreements totaled $346,364 and may include amounts related to unsettled agreements.









ASC 820 establishes a three-level hierarchy for disclosure of fair value measurements. The valuation hierarchy is based upon the transparency of inputs to the valuation of the fund's investments. The three levels are defined as follows:
Level 1: Valuations based on quoted prices for identical securities in active markets.
Level 2: Valuations based on quoted prices in markets that are not active or for which all significant inputs are observable, either directly or indirectly.
Level 3: Valuations based on inputs that are unobservable and significant to the fair value measurement.
The following is a summary of the inputs used to value the fund's net assets as of the close of the reporting period:
  Valuation inputs
Investments in securities: Level 1 Level 2 Level 3
Common stocks*:
Consumer staples $1,192,571 $— $—
Health care 115,536,824 29,893,373



Total common stocks 116,729,395 29,893,373
Short-term investments 20,000 10,379,870



Totals by level $116,749,395 $40,273,243 $—
  Valuation inputs
Other financial instruments: Level 1 Level 2 Level 3
Forward currency contracts $— $(397,548) $—



Totals by level $— $(397,548) $—
* Common stock classifications are presented at the sector level, which may differ from the fund's portfolio presentation.
The volume of activity for the reporting period for any derivative type that was held at the close of the period is listed below and was based on an average of the holdings of that derivative at the end of each fiscal quarter in the reporting period:
Forward currency contracts (contract amount) $31,800,000
For additional information regarding the fund please see the fund's most recent annual or semiannual shareholder report filed on the Securities and Exchange Commission's Web site, www.sec.gov, or visit Putnam's Individual Investor Web site at www.putnaminvestments.com